Medical News & Research

In a randomized open-label trial across 9 VA centers with 764 adults, self-directed CBT with asynchronous personalized feedback reduced pain interference more at 4 months and sustained benefit to 12 months, with few serious adverse events.

In a UK feasibility cohort of 60 older adults with significant cognitive impairment, 92% completed PROM-OPAC in a median 8 minutes, though end effects and limited item variability raise interpretability concerns.

In a phase 1b/2 study of 30 treatment-naive patients with advanced disease, confirmed objective response was 63%, with grade 3 or higher toxicities largely hematologic and no treatment-related discontinuations or deaths.

International multicentre cohort of 708 patients found rare scar recurrence at 1.6% and no scar cancers, with first surveillance beyond 24 months not linked to higher advanced neoplasia risk.